ZYUS Life Sciences Corporation
ZYUS.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -15.52% | 0.58% | -6.15% | 26.23% | 22.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -15.52% | 0.58% | -6.15% | 26.23% | 22.22% |
| Cost of Revenue | 107.61% | -6.58% | -9.40% | -43.95% | -39.14% |
| Gross Profit | -105.57% | 6.62% | -2.79% | 47.16% | 365.18% |
| SG&A Expenses | -6.92% | -25.66% | -7.24% | -55.80% | -27.15% |
| Depreciation & Amortization | -0.70% | -8.04% | -9.57% | -5.54% | -6.71% |
| Other Operating Expenses | -83.33% | -65.92% | 51.04% | 123.50% | -17.76% |
| Total Operating Expenses | -18.04% | -15.28% | 1.09% | -42.80% | -7.76% |
| Operating Income | 18.13% | 15.68% | -1.34% | 43.70% | 8.51% |
| Income Before Tax | 8.80% | 9.39% | -10.85% | 23.68% | 8.17% |
| Income Tax Expenses | -- | -- | -- | 65.81% | 20.38% |
| Earnings from Continuing Operations | 8.40% | 9.07% | -11.42% | 13.72% | 8.11% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 8.40% | 9.07% | -11.42% | 13.72% | 8.11% |
| EBIT | 18.13% | 15.68% | -1.34% | 43.70% | 8.51% |
| EBITDA | 22.40% | 17.10% | -4.54% | 45.05% | 8.94% |
| EPS Basic | 15.08% | 14.72% | -6.30% | 18.72% | 11.16% |
| Normalized Basic EPS | 15.60% | 15.11% | -5.45% | 54.73% | 11.03% |
| EPS Diluted | 8.79% | 15.23% | 0.00% | 19.19% | 11.16% |
| Normalized Diluted EPS | 15.60% | 15.11% | -5.45% | 54.73% | 11.03% |
| Average Basic Shares Outstanding | 7.97% | 6.73% | 4.95% | 6.19% | 3.38% |
| Average Diluted Shares Outstanding | 7.97% | 6.73% | 4.95% | 6.19% | 3.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |